Pharma BD Deal Intelligence

Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd.

2026 · Licensing/Option · Complete

Canadian commercialization of an approved aflibercept biosimilar

Teva Pharmaceutical Industries and Samsung Bioepis entered a license and commercialization agreement for Opuviz, a biosimilar referencing Eylea (aflibercept), in Canada. Samsung Bioepis is responsible for registration and manufacture of the product while Teva Canada is responsible for commercialization. Opuviz received Health Canada approval in October 2025 across retinal indications including neovascular AMD, diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Financial terms were not disclosed.

Key facts

Announced Jul 09, 2026
Deal type Licensing/Option
Therapeutic area Ophthalmology
Indications Neovascular age-related macular degeneration, Diabetic macular edema, Macular edema secondary to retinal vein occlusion, Myopic choroidal neovascularization
Key assets Opuviz (aflibercept biosimilar, referencing Eylea)
Mechanism Anti-VEGF recombinant fusion protein (aflibercept biosimilar)

Disease & market context

Neovascular & Retinal Vascular Eye Disease

Disease Overview

Opuviz is approved across the major anti-VEGF retinal indications — neovascular (wet) AMD, diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization — leading causes of vision loss treated with repeated intravitreal anti-VEGF injections.

Competitive Landscape

Opuviz is a biosimilar to Eylea (aflibercept, Regeneron/Bayer) and competes with reference aflibercept and other anti-VEGF agents including ranibizumab (Lucentis) and faricimab (Vabysmo); biosimilar entry targets cost reduction in the Canadian market.

Deal timeline

Jul 09, 2026
Teva Canada to commercialize Samsung Bioepis' Opuviz aflibercept biosimilar
Teva Canada gains Canadian commercialization rights to Opuviz (aflibercept biosimilar to Eylea); Samsung Bioepis handles registration and manufacture. Financial terms undisclosed.
Channel-fit biosimilar commercialization; terms undisclosed
Adds an approved ophthalmology biosimilar to Teva Canada's portfolio; deal economics not disclosed and launch timing pending.

Related deals — scored

Deal	Year	Value	Outcome
Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. (this deal)	2026	—	51
Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals	2015	$3.5B	86
Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical	1995	—	82
Teva Pharmaceutical Industries Ltd. / Sicor Inc.	2003	$3.4B	68
Teva Pharmaceutical Industries Ltd. / Ivax Corporation	2006	$7.4B	63
Teva Pharmaceutical Industries Ltd. / Novopharm Limited	2000	$600M	62
Teva Pharmaceutical Industries Ltd. / Ivax Corporation	2005	$7.4B	62

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2026 deals · Teva Pharmaceutical Industries Ltd. deals · Ophthalmology deals